Status Quo Senate Still Means Big Changes For FDA Oversight
Executive Summary
The mid-term elections left the US Senate under Democratic leadership – but there are still big changes coming that may make life tougher on FDA and the brand name industry.
You may also be interested in...
US CDC Leadership Transition Set; Timing Sidesteps Potential Rx Pricing Debate
President Biden has selected a new director for the US Centers for Disease Control and Prevention, and the pick – former CMS official Mandy Cohen – is likely to be the last who is not subject to confirmation in the Senate. That is an important nuance in the current political climate for drug pricing policies.
As US House Changes Hands, CMS May Face More Oversight Than FDA
Key Republican committee chairs on health issues are familiar faces, largely supportive of the US FDA’s approach to drug regulation. Implementation of the new pricing law, however, will get a lot more scrutiny.
Medicare And Lecanemab: House Republicans Lack ‘Proactive’ Plan For Ensuring Coverage
With a slim House majority, will Republicans wade into Medicare coverage policy for a promising Alzheimer’s drug and the new Medicare price negotiation program? Democratic Senate could offer ‘counter oversight’ hearings.